TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03412812

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose Escalated Five Fraction Stereotactic Radiosurgery
Description: As focal radiation techniques are utilized more frequently in the treatment of brain metastases, there is increasing need to accurately define the appropriate patient and tumor characteristics for focal therapy. Unfortunately, not all patients are good candidates for single fraction stereotactic radiosurgery (SRS) since large tumors and those in unfavorable locations have been associated with unacceptable rates of treatment-related toxicity. Five fraction stereotactic radiation has proven to be a more effective treatment for these patients that aren't good candidates.
Study: NCT01650649

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lofexidine-matching sugar pill
Description: Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc)as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.
Study: NCT04975412

Intervention type: DIAGNOSTIC_TEST
Intervention: Whole blood zinc level
Description: whole blood zinc levels determined through ashing acid digestion-inductively coupled plasma (ICP) using Shimadzu ICPS-7510, an inductively coupled plasma emission spectrometer.
Study: NCT05036837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZOPROMAF_SEQ1
Description: OZOPROMAF protocol consists of: local superficial anesthesia by EMLA® cream, intra-tissue injection of a 15 ml OxigenOzone (mixture by 26Gx 1⁄2 - 0.45x13mm needle into the mucosal margin surrounding the bone exposure or around the situs already evidenced by CT scan. It is applied on 7-15 days, depending on the patient compliance, until the formation of sequestrum and clinical healing (T1).~Pain intensity is assessed by means of a questionnaire for pain and/or other symptoms evaluation before and after the protocol, based on numerical rating scale (NRS).~After resolution (T1), follow-up visits are scheduled to confirm the healing of MRONJ at 1 (T2), 3, 6 (T3), 12 (T4), 18- 24 months (T5).~Radiographic evaluations of bone healing are scheduled at T3 and T4.~Positive outcomes for the OZOPROMAF protocol are evaluated at T1 as no clinical signs of acute phlogosis and no symptoms compatible with MRONJ; at T5 as clinical healing and no radiological signs of MRONJ.
Study: NCT03980509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin is an extract from turmeric
Study: NCT05178745

Intervention type: DRUG
Intervention: Fluorouracil
Description: Pharmaceutical Form: solution for injection Route of Administration: intravenous (IV), intravenous or intra-arterial infusion

Intervention type: DRUG
Intervention: Aflibercept
Description: Pharmaceutical Form: concentrate solution for infusion Route of Administration: IV infusion

Intervention type: DRUG
Intervention: Irinotecan
Description: Pharmaceutical Form: solution for injection Route of Administration: IV infusion
Study: NCT02993315

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nDC vaccination
Study: NCT02128113

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Ophthalmic Solution
Description: Opthalmic suspension manufactured to mimic RTA 408 suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Ophthalmic Suspension 0.5%
Description: 0.5% ophthalmic suspension of RTA 408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Ophthalmic Suspension 1%
Description: 1% ophthalmic suspension of RTA 408
Study: NCT01645124

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phlebotomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Study: NCT03784170

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: FemPulse System
Description: Device therapy with the FemPulse System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FemPulse System
Description: Device therapy with the FemPulse System
Study: NCT00355888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBP-426
Description: Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.
Study: NCT00936416

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inulin and PAH clearance and MRI
Description: GFR and renal blood flow estimation by Inulin and PAH clearance will be performed in the Renal Physiology Lab for approximately 2.5 hours;~The MRI test will be performed afterwards at Medical Imaging department and last about 45 minutes.
Study: NCT03987243

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Structured Pressure Ulcer Prevention Education
Description: Structured education for performance weight shift maneuvers and pressure ulcer prevention will occur during the initial visit for each subject. The education method used aligns with principles of the social cognitive theory to facilitate learning. The purpose in providing the education is to ensure all of the participants receive uniform instruction in how to perform weight shifts and to facilitate understanding of the importance of completing them as a protective measure against pressure ulcer development. Because each participant will come into the study at varying levels of understanding about pressure ulcer risk and knowledge of how to complete weight shift maneuvers, the education component is critical to ensure all participants are provided with the same information in the same way.

Intervention type: OTHER
Group type: OTHER
Intervention: Mobile Seat Interface Pressure Mapping System (IPM)
Description: This mobile IPM system was designed to provide visual information about seat interface pressure distribution to compensate for lack of sensation on the sitting surface. This variable will be toggled on and off between the intervention and control phases of the study. The participants will have access to the visual feedback while learning how to complete weight shift maneuvers at the initial visit and then again at home during the intervention phases (weeks 2 and 4). During the control phases (weeks 1 and 3), they will not have access to the visual feedback from the pressure map
Study: NCT00978016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arbaclofen placarbil-Cohort 1
Description: After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 20 mg QD) for 7 weeks including titration and taper periods

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Cohort 5
Description: After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (placebo) for 7 weeks including titration and taper periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arbaclofen placarbil-Cohort 2
Description: After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 40 mg QD) with for 7 weeks including titration and taper periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arbaclofen placarbil-Cohort 3
Description: After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 20 mg BID) for 7 weeks including titration and taper periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arbaclofen placarbil-Cohort 4
Description: After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 30 mg BID) for 7 weeks including titration and taper periods

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PPI
Description: Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI
Description: Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI
Description: Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI
Description: Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI
Description: Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD
Study: NCT02132949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Participants will receive 5-fluorouracil 500 mg/m\^2 IV on Day 1 of each cycle q3w.
Study: NCT00152828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Study: NCT02132949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants will receive cyclophosphamide 600 milligrams per square meter (mg/m\^2) intravenous (IV) given on Day 1 of each cycle q2w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants will receive cyclophosphamide 600 milligrams per square meter (mg/m\^2) intravenous (IV) given on Day 1 of each cycle q2w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants will receive docetaxel at a starting dose of 75 mg/m\^2 IV for the first cycle and the dose may be escalated to 100 mg/m\^2 for subsequent cycles q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Participants will receive doxorubicin 60 mg/m\^2 IV on Day 1 of each cycle q2w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Participants will receive epirubicin 100 mg/m\^2 IV on Day 1 of each cycle q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Participants will receive paclitaxel 80 mg/m\^2 IV given weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Participants will receive pertuzumab at a loading dose of 840 milligrams (mg) IV loading dose, then 420 mg IV q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Participants will receive pertuzumab at a loading dose of 840 milligrams (mg) IV loading dose, then 420 mg IV q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Participants will receive trastuzumab at a loading dose of 8 milligrams per kilogram (mg/kg) IV, then 6 mg/kg IV q3w.
Study: NCT03352466

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NasoShield
Description: NasoShield is an adenovirus-vectored anthrax vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NasoShield
Description: NasoShield is an adenovirus-vectored anthrax vaccine.
Study: NCT01025791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match MK-8266 0.1 or 1.0 mg. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match MK-8266 0.1 or 1.0 mg. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match MK-8266 0.1 or 1.0 mg. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match MK-8266 0.1 or 1.0 mg. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match MK-8266 0.1 or 1.0 mg. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
Study: NCT02993315

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo injection
Study: NCT02388048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib + ofatumumab
Study: NCT01025791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match MK-8266 0.1 or 1.0 mg. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match MK-8266 0.1 or 1.0 mg. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match MK-8266 0.1 or 1.0 mg. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match MK-8266 0.1 or 1.0 mg. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match MK-8266 0.1 or 1.0 mg. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match MK-8266 0.1 or 1.0 mg. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
Study: NCT01325298

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UV-X Light
Description: UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
Study: NCT02132949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Participants will receive trastuzumab at a loading dose of 8 milligrams per kilogram (mg/kg) IV, then 6 mg/kg IV q3w.
Study: NCT01768793

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Parents As Teachers (PAT)
Description: Participants will receive visits by Parent Educators, who will deliver the standard PAT curriculum. Participants will receive 28 total visits over the course of approximately 2 years.
Study: NCT02437123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Cedar Project mHealth intervention
Study: NCT01768793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents As Teachers Plus (PAT+)
Description: Participants will receive the standard PAT curriculum, plus lifestyle intervention focusing on healthy diet and exercise, through 28 home visits over the course of approximately 2 years.
Study: NCT03948295

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid Challenge
Description: After fasting for 10 hours, all participants will undergo a lipid challenge with Calogen. Calogen is a commercially available liquid high-energy long chain triglyceride fat emulsion used to fortify foods. Calogen provides 50 grams of long chain triglycerides per 100 mL. Participants must avoid physical activity during the 6 hour study period to avoid changes in metabolism that could affect the results of the study.
Study: NCT01325298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UV-X Light
Description: UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
Study: NCT03445104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Huperzine A
Description: During one of the two experimental sessions, participants will be given huperzine A.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During one of the two experimental sessions, participants will be given a placebo.
Study: NCT02927431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danirixin 15 mg FBE
Description: This intervention is available as a 50 mg FBE sterile lyophilized powder containing DNX (hydrobromide salt hemihydrate) equivalent to 50mg of free base along with Beta-cyclodextrin sulfobutylether, mannitol, citric acid and sodium hydroxide. The formulation is supplied as lyophilized powder/cake contained in a 30mL vial. Each vial is reconstituted with 9.5 mL water for injection and further diluted with saline for IV infusion to provide a dose of 15 mg FBE.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danirixin 50 mg FBE
Description: This intervention is available as a 50 mg FBE sterile lyophilized powder containing DNX (hydrobromide salt hemihydrate) equivalent to 50mg of free base along with Beta-cyclodextrin sulfobutylether, mannitol, citric acid and sodium hydroxide. The formulation is supplied as lyophilized powder/cake contained in a 30mL vial. Each vial is reconstituted with 9.5 mL water for injection and further diluted with saline for IV infusion.
Study: NCT04267926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 mg MitoQ
Description: a third of subject will receive 20mg of oral MitoQ

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject will receive Placebo
Study: NCT03352466

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NasoShield
Description: NasoShield is an adenovirus-vectored anthrax vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NasoShield
Description: NasoShield is an adenovirus-vectored anthrax vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BioThrax
Description: Commercially available anthrax vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT04267926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40mg of MitoQ
Description: a third of subjects will receive 40mg of MitoQ
Study: NCT02927431

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No vials of placebo to match IV DNX will be provided. A normal saline solution of matched volume will be prepared by unblinded personnel at the site to act as a placebo to DNX. Clear solution of placebo will be administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg
Description: Oseltamivir (Tamiflu - manufactured by Roche) formulation is available as 75 mg Capsule and as powder for oral suspension. After constitution with 55 mL of water, each bottle delivers a usable volume of 60 mL of oral suspension equivalent to 360 mg oseltamivir base (6 mg/mL). No oseltamivir capsules or powder for oral suspension will be provided. Sites will source the OSV locally and it will be provided open-label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg
Description: Oseltamivir (Tamiflu - manufactured by Roche) formulation is available as 75 mg Capsule and as powder for oral suspension. After constitution with 55 mL of water, each bottle delivers a usable volume of 60 mL of oral suspension equivalent to 360 mg oseltamivir base (6 mg/mL). No oseltamivir capsules or powder for oral suspension will be provided. Sites will source the OSV locally and it will be provided open-label.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oseltamivir 75 mg
Description: Oseltamivir (Tamiflu - manufactured by Roche) formulation is available as 75 mg Capsule and as powder for oral suspension. After constitution with 55 mL of water, each bottle delivers a usable volume of 60 mL of oral suspension equivalent to 360 mg oseltamivir base (6 mg/mL). No oseltamivir capsules or powder for oral suspension will be provided. Sites will source the OSV locally and it will be provided open-label.
Study: NCT01385215

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluzone
Description: 0.5 ml/15 micrograms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluzone
Description: 0.5 ml/60 micrograms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluzone
Description: 0.5 ml/60 micrograms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluzone
Description: 0.5 ml/60 micrograms
Study: NCT02602496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruits and Vegetables
Description: 5 servings of fruits or vegetables

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Grain
Description: 3 servings of whole grain
Study: NCT03256240

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: side-to-side functional end anastomosis
Description: type of anastomosis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kono-S analstomosis
Description: antimesenteric anastomosis